Pazopanib (Votrient®) is an oral small-molecule multi-kinase inhibitor that primarily inhibits
vascular endothelial growth factor receptor-1,-2 and-3, platelet endothelial growth factor …

Therapy for metastatic renal cell carcinoma should be tailored to the circumstances and
preferences of the individual patient. Age should not be a barrier to effective treatment …

Background Metastatic renal cell carcinoma (RCC) patients are commonly treated with
vascular endothelial growth factor (VEGF) inhibitors or mammalian target of rapamycin …

PURPOSE To better understand the European Society for Medical Oncology-Magnitude of
Clinical Benefit Scale version 1.1 (ESMO-MCBS v1. 1) and the ASCO Value Framework Net …

Purpose: Glutaminase is a key enzyme, which supports elevated dependency of tumors on
glutamine-dependent biosynthesis of metabolic intermediates. Dual targeting of glucose and …

Purpose: Dual inhibition of glucose and glutamine metabolism results in synergistic
anticancer effects in solid tumor models. Telaglenastat, an investigational, small-molecule …

Although decision making strategy based on clinico-histopathological criteria is well
established, renal cell carcinoma (RCC) represents a spectrum of biological ecosystems …

Purpose: High body mass index (BMI) may lead to improved immune-checkpoint blockade
(ICB) outcomes in metastatic clear cell renal cell carcinoma (mccRCC). However, BMI is a …

The most common type of cancer originating in the kidney is renal cell carcinoma (RCC). In
both localized and advanced RCC, a number of clinical, pathologic, and molecular factors …

Since 2005, the approved first-line treatment of metastatic renal cell carcinoma consists in
tyrosine kinase inhibitors (TKIs) targeting the vascular endothelial growth factor receptors …